Ayala Pharmaceuticals Inc.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Advaxis, Inc. (to 2025)
5
Ending by 2030
Nov 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 21, 2027The maintenance fee for Compositions and Methods for Prevention of Escape Mutation in the Treatment of HER2/NEU Over-Expressing Tumors (US 9,084,747) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,012,141 | Compositions and methods comprising KLK3 of FOLH1 antigen In force · High confidence | In force | High confidence | |
| US 9,650,639 | Dual delivery system for heterologous antigens In force · From the USPTO record | In force | From the USPTO record | |
| US 9,644,212 | Dual delivery system for heterologous antigens In force · From the USPTO record | In force | From the USPTO record | |
| US 10,064,898 | Listeria-Based Adjuvants In force · Low confidence | In force | Low confidence | |
| US 9,463,227 | Listeria-Based Adjuvants In force · Medium confidence | In force | Medium confidence | |
| US 9,017,660 | Compositions and Methods for Prevention of Escape Mutation in the Treatment of HER2/NEU Over-Expressing Tumors In force · High confidence | In force | High confidence | |
| US 9,084,747 | Compositions and Methods for Prevention of Escape Mutation in the Treatment of HER2/NEU Over-Expressing Tumors In force · Medium confidence | In force | Medium confidence | |
| US 10,058,599 | Suppressor cell function inhibition following Listeria vaccine treatment In force · From the USPTO record | In force | From the USPTO record | |
| US 10,258,679 | Recombinant Listeria vaccine strains and methods of producing the same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,179,339 | Compositions and Methods for Lyophilization of Bacteria or Listeria Strains In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 3 patents in force now held by others · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 abandoned · 5 no status recorded